Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen, LAVA to Develop Cell Lines for Bispecific Candidate | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

ProBioGen, LAVA to Develop Cell Lines for Bispecific Candidate

ProBioGen will conduct cell line development of a novel gamma-delta bsTCE using its CHO.RiGHT expression platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen and LAVA Therapeutics N.V. entered a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA’s pipeline.
 
ProBioGen will conduct cell line development of a novel gamma-delta bsTCE using its CHO.RiGHT expression platform, including its DirectedLuck Transposase technology for the generation of stable high-titer cell lines
 
“We are delighted to continue our collaboration with LAVA to develop cell lines for another novel gamma-delta bsTCE. Our proven cell line development platform, which also includes our Transposase technology, is perfectly suited for novel protein formats,” said ProBioGen’s Chief Executive Officer Dr. Lutz Hilbrich.
 
“Based on the great results from our previous agreement, we would look forward working with ProBioGen again,” said Stephen Hurly, Chief Executive Officer and President of LAVA Therapeutics. “ProBioGen exceeded our expectations and proved to be a scientifically driven partner with a proven development platform and a dedicated analytical panel for bispecific antibody formats.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics